CEO, Troy Grogan Interviewed by Proactive Investors

Nov 25

CEO Troy Grogan tells Proactive the group is gaining traction with its cloud-based software as a Medical Device system QHSLab, together with increased revenue growth from its distribution agreement with MedScience Research Group.

Grogan says the distribution agreement has allowed the Florida-based digital medicine company to begin generating revenue by shipping the allergy diagnostic products to its physician customers. What's more, Grogan says the group is gaining traction from its initial QHSLab beta launch, expecting to 'turn on' the model for physicians using the product in 2021.

Olivia Giamanco

CEO, Troy Grogan Interviewed by Proactive Investors

CEO Troy Grogan tells Proactive the group is gaining traction with its cloud-based software as a Medical Device system QHSLab, together with increased revenue growth from its distribution agreement with MedScience Research Group.

USAQ and AllergiEnd® Announce Allergy Testing Kit Distribution Ahead of COVID-19 Vaccine

Medical Practice Income, a Subsidiary of USAQ, Announces Exclusive Distribution Agreement with MedScience Research Group